Today, the EVP, Chief Medical Officer of Mirati Therapeutics, Isan Chen, exercised options of Mirati Therapeutics (NASDAQ: MRTX) for $39.03K.
Following Isan Chen’s last MRTX Buy transaction on April 26, 2018, the stock climbed by 19.6%. This recent transaction increases Isan Chen’s holding in the company by 6.15% to a total of $1.78 million.
See today’s analyst top recommended stocks >>
Based on Mirati Therapeutics’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $9.47 million and GAAP net loss of $14.71 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $18.34 million. Currently, Mirati Therapeutics has an average volume of 225.9K. The Company has a Price to Book ratio of 10.8341.
14 different firms, including Barclays and Brean Capital, currently also have a Buy rating on the stock. Starting in May 2018, MRTX received 5 Buy ratings in a row. Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $51.60, reflecting a -0.3% downside.
The insider sentiment on Mirati Therapeutics has been positive according to 25 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat.
